Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
So even though there were steps that employees had to take, it was usually denied the first time and they had to go through an appeal process
The Rise of GLP-1 Therapies for Obesity and Type 2 Diabetes GLP-1 RAs: A Paradigm Shift GLP-1 RAs have revolutionized the treatment of both T2DM and obesity
Do it for a full week
However, large meta-analyses and regulatory reviews have not established a definitive causal relationship
According to FDA prescribing information, these effects vary by product and dose: For Ozempic (diabetes treatment): Nausea (15-20% of patients) Diarrhea (8-9% of patients) Vomiting (5-9% of patients) Constipation (3-7% of patients) Abdominal pain (5-6% of patients) For Wegovy (weight management), gastrointestinal effects are more common at the higher therapeutic dose: Nausea (up to 44% of patients) Diarrhea (up to 30% of patients) Vomiting (up to 24% of patients) Constipation (up to 24% of patients) Abdominal pain (up to 20% of patients) These effects are generally mild to moderate and tend to diminish with continued use
Keep reading to explore how Scitons treatment suite can help providers address the skin changes that often accompany GLP-1 use
